Medical Research
(H30)
990 on File
STL CURE SARCOMA
Financial strength (30%)
66/100
Reliability (20%)
40/100
Effectiveness (25%)
61/100
Impact (25%)
No data yet
CharityAI™ Score
Not yet evaluated
Financial Overview — FY 2025
$152K
Total Revenue
$111K
Total Expenses
$145K
Net Assets
N/A
Employees
Revenue Sources
Expense Breakdown
Program Expense Ratio
96.6%
Fundraising Efficiency
N/A
Operating Reserve
15.70x
Liability-to-Asset
0.0%
Revenue Diversification
78.0%
Compared with Peers
FY 2025
Compared with 300 similar organizations
(United States, Medical Research, $100K–$1M in expenses), FY 2025.
This organization
Middle half of peers (P25–P75)
Peer median
| Ratio | This org | Peer median | Position (P10 → P90) | |
|---|---|---|---|---|
|
Program expense ratio
Program expenses / total expenses
· higher is better
|
96.6% | 84.6% |
P10P90
|
Top quarter |
|
Operating reserve
Months of expenses covered by net assets
· higher is better
|
15.7 mo | 11.7 mo |
P10P90
|
Above median |
|
Liabilities to assets
Total liabilities / total assets
· lower is better
|
0.0% | 0.0% |
P10P90
|
Top quarter |
|
Revenue concentration
Share of revenue from the largest source
· lower is better
|
78.0% | 92.2% |
P10P90
|
Above median |
|
Revenue growth
Year over year revenue growth
|
19.9% | 3.4% |
P10P90
|
|
|
Expense growth
Year over year expense growth
|
341.5% | 7.5% |
P10P90
|
|
|
Surplus margin
Surplus as a share of revenue
|
27.1% | -1.6% |
P10P90
|
Financial History
| Year | Revenue | Expenses | Net Assets | Program % | Staff |
|---|---|---|---|---|---|
| 2025 | $152K | $111K | $145K | 96.6% | — |
| 2024 | $127K | $25K | $104K | 75.0% | — |
| 2023 | $3K | $1K | $2K | 58.5% | — |
Donor Reviews
Write a ReviewNo reviews yet
Be the first to share your experience with this organization.